Risk factors for skin cancer and solid tumors in newly diagnosed patients with chronic lymphocytic leukemia and the impact of skin surveillance on survival

References

• Forconi F, Moss P. Perturbation of the normal immune system in patients with CLL. Blood. 2015;126:573–581.
   PubMed Web of Science ®Google Scholar
• Beiggi S, Johnston JB, Seftel MD, et al. Increased risk of second malignancies in chronic lymphocytic leukaemia patients as compared with follicular lymphoma patients: a Canadian population-based study. Br J Cancer. 2013;109:1287–1290.
   PubMed Web of Science ®Google Scholar
• Manusow D, Weinerman BH. Subsequent neoplasia in chronic lymphocytic leukemia. JAMA. 1975;232:267–269.
   PubMed Web of Science ®Google Scholar
• Royle J, Baade P, Joske D, et al. Second cancer incidence and cancer mortality among chronic lymphocytic leukaemia patients: a population-based study. Br J Cancer. 2011;105:1076–1081.
   PubMed Web of Science ®Google Scholar
• Molica S. Second neoplasms in chronic lymphocytic leukemia: incidence and pathogenesis with emphasis on the role of different therapies. Leuk Lymphoma. 2005;46:49–54.
   PubMed Web of Science ®Google Scholar
• Brewer JD, Shanafelt TD, Call TG, et al. Increased incidence of malignant melanoma and other rare cutaneous cancers in the setting of chronic lymphocytic leukemia. Int J Dermatol. 2015;54:e287–293.
   PubMed Web of Science ®Google Scholar
• Tadmor T, Aviv a, Polliack a. Merkel cell carcinoma, chronic lymphocytic leukemia and other lymphoproliferative disorders: an old bond with possible new viral ties. Ann Oncol. 2011;22:250–256.
   PubMed Web of Science ®Google Scholar
• Famenini S, Martires KJ, Zhou H, et al. Melanoma in patients with chronic lymphocytic leukemia and non-Hodgkin lymphoma. J Am Acad Dermatol. 2015;72:78–84.
   PubMed Web of Science ®Google Scholar
• Velez NF, Karia PS, Vartanov AR, et al. Association of advanced leukemic stage and skin cancer tumor stage with poor skin cancer outcomes in patients with chronic lymphocytic leukemia. JAMA Dermatol. 2014;150:280–287.
   PubMed Web of Science ®Google Scholar
• Brewer JD, Shanafelt TD, Otley CC, et al. Chronic lymphocytic leukemia is associated with decreased survival of patients with malignant melanoma and merkel cell carcinoma in a SEER population-based study. J Clin Oncol. 2012;30:843–849.
   PubMed Web of Science ®Google Scholar
• Mulcahy A, Mulligan SP, Shumack SP. Recommendations for skin cancer monitoring for patients with chronic lymphocytic leukemia. Leuk Lymphoma. 2018;59:578–582.
   PubMed Web of Science ®Google Scholar
• Hallek M, Cheson BD, Catovsky D, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood. 2008;111:5446–5456.
   PubMed Web of Science ®Google Scholar
• Demers AA, Nugent Z, Mihalcioiu C, et al. Trends of nonmelanoma skin cancer from 1960 through 2000 in a Canadian population. J Am Acad Dermatol. 2005;53:320–328.
   PubMed Web of Science ®Google Scholar
• Nugent Z, Demers AA, Wiseman MC, et al. Risk of second primary cancer and death following a diagnosis of nonmelanoma skin cancer. Cancer Epidemiol Biomarkers Prev. 2005;14:2584–2590.
   PubMed Web of Science ®Google Scholar
• Kost SEF, Bouchard EDJ, Labossière É, et al. Cross-resistance and synergy with bendamustine in chronic lymphocytic leukemia. Leuk Res. 2016;50:63–71.
   PubMed Web of Science ®Google Scholar
• Solomon BM, Chaffee KG, Moreira J, et al. Risk of non-hematologic cancer in individuals with high-count monoclonal B-cell lymphocytosis. Leukemia. 2016;30:331–336.
   PubMed Web of Science ®Google Scholar
• Solomon BM, Rabe KG, Slager SL, et al. Overall and cancer-specific survival of patients with breast, colon, kidney, and lung cancers with and without chronic lymphocytic leukemia: a SEER population-based study. J Clin Oncol. 2013;31:930–937.
   PubMed Web of Science ®Google Scholar
• Brewer JD, Shanafelt TD, Khezri F, et al. Increased incidence and recurrence rates of nonmelanoma skin cancer in patients with non-Hodgkin lymphoma: a Rochester epidemiology project population-based study in Minnesota. J Am Acad Dermatol. 2015;72:302–309.
   PubMed Web of Science ®Google Scholar
• Royle JS, Baade P, Joske D, et al. Risk of second cancer after lymphohematopoietic neoplasm. Int J Cancer. 2011;129:910–919.
   PubMed Web of Science ®Google Scholar
• Walz JS, Kowalewski DJ, Backert L, et al. Favorable immune signature in CLL patients, defined by antigen-specific T-cell responses, might prevent second skin cancers. Leuk Lymphoma. 2018;8194:1–10.
   Google Scholar
• Beiggi S, Banerji V, Deneka A, et al. Comparison of outcome between referred and non-referred chronic lymphocytic leukemia patients to a specialized CLL clinic: a Canadian-based study. Cancer Med. 2016;5:971–979.
   PubMed Web of Science ®Google Scholar
• Tsai H, Caporaso NE, Kyle RA, et al. Evidence of serum immunoglobulin abnormalities up to 9.8 years before diagnosis of chronic lymphocytic leukemia: a prospective study. Blood. 2009;114:4928–4932.
   PubMed Web of Science ®Google Scholar
• Landgren O, Rapkin JSJ, Caporaso NE, et al. Respiratory tract infections and subsequent risk of chronic lymphocytic leukemia. Blood. 2007;109:2198–2201.
   PubMed Web of Science ®Google Scholar
• Moreira J, Rabe KG, Cerhan JR, et al. Infectious complications among individuals with clinical monoclonal B-cell lymphocytosis (MBL): a cohort study of newly diagnosed cases compared to controls. Leukemia. 2013;27:136–141.
   PubMed Web of Science ®Google Scholar
• Mansfield BAS, Rabe KG, Slager SL, et al. Skin cancer surveillance and malignancies of the skin in a community-dwelling cohort of patients with newly diagnosed chronic lymphocytic leukemia. J Oncol Pract. 2014;10:e1–4.
   PubMedGoogle Scholar
• Hock BD, McIntosh ND, McKenzie JL, et al. Incidence of cutaneous squamous cell carcinoma in a New Zealand population of chronic lymphocytic leukaemia patients. Intern Med J. 2016;46:1414–1421.
   PubMed Web of Science ®Google Scholar
• Tsimberidou AM, Wen S, McLaughlin P, et al. Other malignancies in chronic lymphocytic leukemia/small lymphocytic lymphoma. J Clin Oncol. 2009;27:904–910.
   PubMed Web of Science ®Google Scholar
• Hallek M. Chronic lymphocytic leukemia: 2017 update on diagnosis, risk stratification, and treatment. Am J Hematol. 2017;92:946–965.
   PubMed Web of Science ®Google Scholar
• Long M, Beckwith K, Do P, et al. Ibrutinib treatment improves T cell number and function in CLL patients. J Clin Invest. 2017;127:3052–3064.
   PubMed Web of Science ®Google Scholar
• Pleyer C, Wiestner A, Sun C. Immunological changes with kinase inhibitor therapy for chronic lymphocytic leukemia. Leuk Lymphoma. 2018;59:2792–2800.
   PubMed Web of Science ®Google Scholar
• Teh BW, Chui W, Handunnetti S, et al. High rates of proven invasive fungal disease with the use of ibrutinib monotherapy for relapsed or refractory chronic lymphocytic leukemia. Leuk Lymphoma. 2019;60:1572–1575.
   PubMed Web of Science ®Google Scholar
• Maschmeyer G, De Greef J, Mellinghoff SC, et al. Infections associated with immunotherapeutic and molecular targeted agents in hematology and oncology. A position paper by the European Conference on Infections in Leukemia (ECIL). Leukemia. 2019;33:844–862.
   Google Scholar
• Mehrany K, Weenig RH, Pittelkow MR, et al. High recurrence rates of squamous cell carcinoma after Mohs ’ surgery in patients with chronic lymphocytic leukemia. Am Soc Dermatol Surg. 2004;31:985–988.
   Web of Science ®Google Scholar
• Davis JW, Weiss NS, Armstrong BK. Second cancers in patients with chronic lymphocytic leukemia. J Natl Cancer Inst. 1987;78:91–94.
   PubMed Web of Science ®Google Scholar
• Falchi L, Vitale C, Keating MJ, et al. Incidence and prognostic impact of other cancers in a population of long-term survivors of chronic lymphocytic leukemia. Ann Oncol. 2016;27:1100–1106.
   PubMed Web of Science ®Google Scholar
• Benjamini O, Jain P, Trinh L, et al. Second cancers in patients with chronic lymphocytic leukemia who received frontline fludarabine, cyclophosphamide and rituximab therapy: distribution and clinical outcomes. Leuk Lymphoma. 2015;56:1643–1650.
   PubMed Web of Science ®Google Scholar
• Hisada M, Biggar RJ, Greene MH, et al. Solid tumors after chronic lymphocytic leukemia. Blood. 2001;98:1979–1981.
   PubMed Web of Science ®Google Scholar